Oncology Data Advisor® · What Are Ethical Dilemmas in Research Nursing, and How Do We Manage Them? With Doyle Bosque At the 48th Oncology Nursing Society (ONS) Congress, Doyle Bosque, Director of Nursing Programs Research at MD Anderson Cancer Center, sat down with Oncology Data Advisor® to further discuss and expand upon his presentation Management of Ethical Dilemmas: The Needs of the Research Nursing Community.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, ...

This year's Oncology Nursing Society (ONS) Congress featured numerous thought-provoking and motivating presentations from experts in the field of oncology nursing. Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center and Editorial Board Member of Oncology Data Advisor®, stopped by in between presentations to share the most inspiring topics that she enjoyed hearing and is looking forward to sharing with her team.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today ...

Oncology Data Advisor® · Creating Welcoming Spaces for LGBTQ+ Cancer Survivorship Care At the 48th Annual Oncology Nursing Society (ONS) Congress, Dr. Megan Mullins, an Assistant Professor at the University of Texas (UT) Southwestern Cancer Center, gave a presentation on improving cancer survivorship for sexual and gender minorities. In this follow-up interview, she shares the ongoing efforts into improving cancer survivorship care for these populations, as well as advice and resource...

The FDA has approved epcoritamab-bysp (Epkinly™, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified. This approval includes high-grade B-cell lymphoma after two or more lines of systemic therapy and DLBCL arising from indolent lymphoma.   Why it matters: "Treatment regimens incorporating anti-CD20 monoclonal antibodies have become the standard of care for DLBCL and follicular lymphoma; however, intrinsic or acquired resistance will occ...

Oncology Data Advisor® · How to Empower Bedside Oncology Nurses as Leaders: Tammy Triglianos, DNP, ANP-BC, AOCNP At the recent 48th Oncology Nursing Society (ONS) Congress, Tammy Triglianos, DNP, ANP-BC, AOCNP, a certified Adult Oncology Nurse Practitioner at the University of North Carolina School of Nursing, sat down to further discuss her presentation Empowering Bedside Oncology Nurses as Leaders.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ...

Oncology Data Advisor® · Staying Proficient in Managing Chronic Cancer-Related Pain: Tanya Uritsky, PharmD At the recent 48th Oncology Nursing Society (ONS) Congress, Tanya Uritsky, PharmD, the Opioid Stewardship Coordinator at the Hospital of the University of Pennsylvania, sat down with Oncology Data Advisor to discuss her presentation When Pain Holds a Grudge, Give It a Nudge! Best Practices for Managing Chronic Cancer-Related Pain. Her talk encompasses new and novel interventional...

Oncology Data Advisor® · Piloting Melanoma Research and Local Cancer Care With Richard Carvajal, MD This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-...

Oncology Data Advisor® · Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, discusses the educational topics that he is looking forward to sharing his insights on as a Fellows Forum...

Oncology Data Advisor® · ONS Live Podcast: Staying Proficient in Managing Chronic Cancer-Related Pain Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Tanya Uritsky, the Opioid Stewardship Coordinator at the Hospital of the University of Pennsylvania, discusses her presentation When Pain Holds a Grudge, Give It a Nudge! Best Practices for Managing Chronic Cancer-Related Pain. Her talk encompasses new and novel interventional thera...

Oncology Data Advisor® · Creating an Informed Approach to Mental and Emotional Trauma Experienced by Cancer Patients Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Elizabeth Archer-Nanda, Founding Member of the Behavioral Oncology Program and Clinical Director of Advanced Practice Providers at Norton Cancer Institute, and Meagan Dwyer, a Licensed Clinical Psychologist, discuss their presentation Compassionate Canc...

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years regarding leukemia research.  Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows For...

Oncology Data Advisor® · ONS Live Podcast: Healthcare Violence Trends And Prevention Strategies Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Scott Christensen, Senior Nursing Director at the University of Utah, discusses his presentation regarding Safety and Violence in Healthcare. His talk encompasses the trends in workplace violence and potential strategies to prevent such instances to help protect staff.  Transcript will be avai...

Oncology Data Advisor® · Driving Health Care Accessibility Through Acute Myeloid Leukemia Research With Ian Bouligny, MD In this interview for National Minority Health Month, Oncology Data Advisor speaks with Dr. Ian Bouligny, a third-year Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Bouligny shares updates on his research regarding health care barriers faced by patients of minority populations with acute myeloid leukemia (AML) and sug...

The FDA has approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL); including those who have an International Prognostic Index (IPI) score of 2 or greater. Why it matters: "Although most patients (depending on prognostic factors) can be cured with R-CHOP (rituximab, cyclo...

The FDA has approved omidubicel-onlv (Omisirge®, Gamida Cell Ltd.) for treatment of adult and pediatric patients 12 and older with hematologic malignancies, to minimize the time to neutrophil recovery and incidence of infection following myeloablative conditioning for umbilical cord transplantation. Approved population: adults and pediatric patients ≥12 with hematologic malignancies Why it matters: "Early-phase studies have demonstrated that ex vivo expansion of umbilical cord blood (UCB) s...

i3 Health recently provided an online continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity that has challenged the health care team's proficiency in managing metastatic squamous non–small cell lung cancer (NSCLC). Lung cancer is the second most common cancer in the United States between both men and women, with the American Cancer Society estimating a total of 238,340 new cases being diagnosed and 127,070 deaths occurring throughout 2023. Appr...

The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev®, Astellas Pharma) with pembrolizumab (Keytruda®, Merck) for treatment of locally advanced or metastatic urothelial carcinoma, specifically for patients who are ineligible for cisplatin-containing chemotherapy. "Both enfortumab vedotin and pembrolizumab are effective monotherapy treatments in patients with locally advanced or metastatic urothelial carcinoma," began Christopher Hoimes, Associate Professor of Medicine at t...

Oncology Data Advisor™ · Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, "Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval." In this interview with OncData, he further discusses his resea...

Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, "Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval." In this interview with OncData, he further discusses his research and gives a thought-provoking analysis of what these findings could mean for the future of the accelerated app...

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as both a Video Viewpoint Strategy Session and a podcast, provided significant gains in proficiency amongst the health care professionals who participated....